CTLA4 and neoplasm: As a complement, the IMvigor210 cohort and GSE63557 cohort, a dataset of urothelial cancer patients who received an anti-PD-L1 agent and a dataset of AB1-HA mesothelioma tumour mice treated with anti-CTLA4 therapy were used to investigate the value of the two-gene risk score in predicting the response to immunotherapy [20, 21].